BERKELEY HEIGHTS, N.J., May 31, 2012 (GLOBE NEWSWIRE) -- Genta Incorporated (GNTA) announced today that the first patient has been accrued to a new randomized trial of tesetaxel as initial chemotherapy for women with advanced or recurrent breast cancer. The trial -- a randomized, three-arm, Phase 2b study that is expected to accrue approximately 220 patients -- will be conducted at approximately 15 sites in the U.S. and Western Europe. Accrual is projected to take approximately 12 months, with approximately 12 months of followup. Tesetaxel is the leading oral taxane in clinical development.
